|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) Yale University |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000203 |
Purpose
The purpose of this study is to evaluate varying doses of buprenorphine for opioid dependence and cocaine abuse.
| Condition | Intervention | Phase |
|
Opioid-Related Disorders |
Drug: Buprenorphine |
Phase II |
| ChemIDplus related topics: | Buprenorphine Buprenorphine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Buprenorphine Maintenance for Opioid Addicts |
Eligibility
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, Connecticut | |||||
| VA Connecticut Healthcare System | |||||
| New Haven, Connecticut, United States, 06519 | |||||
| National Institute on Drug Abuse (NIDA) |
| Yale University |
| Principal Investigator: | Thomas R Kosten, M.D. | VA Connecticut Healthcare System |
More Information
| Study ID Numbers: | NIDA-05626-2, R01-05626-2 |
| First Received: | September 20, 1999 |
| Last Updated: | August 23, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000203 |
| Health Authority: | United States: Federal Government |
|
|
|